Desmoteplase
drugOn this page
Also known as DesmoteplasaDspa desmoteplaseRDSPA ALPHA 1
Summary
Desmoteplase (CHEMBL2109084) is a phase-3 clinical-stage enzyme; indicated across 2 conditions including stroke disorder.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Enzyme
- Indications: 2 conditions
- Clinical trials: 6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109084 |
| Name | Desmoteplase |
| Type | Enzyme |
| Max phase | 3 |
Also known as: Desmoteplasa, Desmoteplase, Dspa desmoteplase, RDSPA ALPHA 1, DESMOTEPLASE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| stroke disorder | 3 | MONDO:0005098 | EFO:0000712 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 6.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 3 |
| PHASE2 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00111852 | PHASE3 | COMPLETED | Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2) |
| NCT00790920 | PHASE3 | COMPLETED | Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke |
| NCT00856661 | PHASE3 | TERMINATED | Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4) |
| NCT00638248 | PHASE1/PHASE2 | COMPLETED | Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS) |
| NCT00638781 | PHASE2 | COMPLETED | Desmoteplase in Acute Ischemic Stroke (DIAS) |
| NCT01104467 | PHASE2 | COMPLETED | Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: stroke disorder